Researchers reveal structure of SARS-CoV-2 Envelope protein
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
List view / Grid view
The molecular structure of the SARS-CoV-2 Envelope protein has been identified by researchers using nuclear magnetic resonance.
A specific furin cleavage motif on the SARS-CoV-2 Spike protein, not present on other coronaviruses (CoVs), could be targeted by novel COVID-19 therapies.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
The SARS-CoV-2 RNA genome structure has been studied by researchers who identified several potential drug targets.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Researchers have found antibodies, from infection with common cold coronaviruses, can also target SARS-CoV-2 - especially in children.
A team has revealed how SARS-CoV-2 infects cells, suggesting that targeting its RNA with drugs would stop the virus replicating.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
According to a new study, the SARS-CoV-2 virus is accumulating genetic mutations, including one called D614G which may have made it more contagious.
By blocking the lymphotoxin beta receptor signalling pathway, researchers were able to prevent COPD progression and induce a full restoration of lung tissue.
Researchers have found the genome of COVID-19 and infected cell syncytia in the respiratory cells of deceased patients, potentially explaining long-term coronavirus effects.
Scientists have shown that age may cause genetically identical melanoma skin cancer cells to respond differently to treatment, making age a primary factor in treatment response.
According to a new study, blood clots in patients with severe COVID-19 are caused by an autoimmune antibody that circulates in the blood and attacks cells.
Certain sensory neurons and Substance P are potential drug targets for the development of novel allergy preventions or treatments, according to scientists.